Abstract
Alendronate is indicated for the treatment of osteoporosis in post-menopausal women. Although the drug has been associated with reports of severe oesophagitis, there have been no studies establishing the incidence of such reactions. Information was collected on 1523 patients included in a study conducted by means of prescription-event monitoring. Dyspepsia, nausea/vomiting, and abdominal pain were the most frequently reported events in the first month of treatment. After follow-up, 20 patients (1.3%) experienced oesophageal events that were considered to be possibly related to alendronate.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Faich G. A. US adverse drug reaction surveillance 1989-1994. Pharmacoepidemiol Drug Saf. 1996 Nov;5(6):393–398. doi: 10.1002/(SICI)1099-1557(199611)5:6<393::AID-PDS235>3.0.CO;2-H. [DOI] [PubMed] [Google Scholar]
- Mann R. D., Wilton L. V., Pearce G. L., Mackay F. J., Dunn N. R. Prescription-event monitoring (PEM) in 1996-a method of non-interventional observational cohort pharmacovigilance. Pharmacoepidemiol Drug Saf. 1997 Oct;6 (Suppl 3):S5–11. doi: 10.1002/(SICI)1099-1557(199710)6:3+<S5::AID-PDS272>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
- McAvoy B. R., Kaner E. F. General practice postal surveys: a questionnaire too far? BMJ. 1996 Sep 21;313(7059):732–734. doi: 10.1136/bmj.313.7059.732. [DOI] [PMC free article] [PubMed] [Google Scholar]
- de Groen P. C., Lubbe D. F., Hirsch L. J., Daifotis A., Stephenson W., Freedholm D., Pryor-Tillotson S., Seleznick M. J., Pinkas H., Wang K. K. Esophagitis associated with the use of alendronate. N Engl J Med. 1996 Oct 3;335(14):1016–1021. doi: 10.1056/NEJM199610033351403. [DOI] [PubMed] [Google Scholar]